The expanded indication for mavacamten offers a novel targeted medical therapy for pediatric patients aged 12 years and older with symptomatic oHCM, backed by data from the phase 3 SCOUT-HCM trial.
Tasimelteon significantly advanced sleep onset by 42.5 minutes in adults with delayed sleep-wake phase disorder, according to topline phase 3 data.
The effect of semaglutide on major adverse cardiovascular events (MACE) is only partially due to known risk factors, according to a study published online September 23 in the European Heart Journal.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results